Overview

A Study to Evaluate the Effect of Clarithromycin on LY2216684

Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The study will evaluate the effect of Clarithromycin on the pharmacokinetics (PK) of LY2216684 in healthy participants. Side effects will be documented. There will be 2 study periods (5 and 9 days) and follow up will occur at least 7 days after the last dose. Screening is required within 45 days prior to the start of the study.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Clarithromycin
Phenylethyl Alcohol